Already have an account?


Login with an existing Projects In Knowledge account
New to Projects In Knowledge?


Register today to customize your experience.
Log In
Don't have an account yet? Click here to register



Register for Free
Already have an account? Click here to log in



Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.



Forgot Password

Please Enter your email address.




  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy
www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

Revision date: This policy was last updated on September 30, 2003.



New and Noteworthy
Education Initiative in Cardiology

  • Heart Failure — AHA: Can HF Clinical Practice Keep Pace with the Evidence? – BreakingMED
  • Practicing evidence-based medicine can be difficult when the evidence keeps coming at a fast and furious pace, which may be a factor in the ongoing disconnect between “evidence” and “practice” in the clinical management of heart failure. The latest confirmation of this conundrum comes from a study by Muthiah ... more >>
    V. Abramson, MD
  • Heart Failure — AHA: The Funder Pulled Out, But Sotagliflozin Trials May Pull Off a Surprising Win – BreakingMED
  • A pair of trials of a novel inhibitor of sodium-glucose cotransporter 1 and 2 (SGLT1/2i) offer the first tantalizing hint of a treatment that appears to demonstrate efficacy not only for reduced ejection fraction heart failure (HFrEF) but also for preserved ejection fraction heart failure (HFpEF). Both trials ... more >>
    V. Abramson, MD
  • Heart Failure — AHA: IV Iron Supplementation May Improve Outcomes in HFrEF – BreakingMED
  • As many as 80% of patients with heart failure are known to have iron deficiency but checking for iron deficiency is not a routine part of clinical management. However, that may soon change as results of a double-blind, randomized trial suggest that an infusion of ferric carboxymaltose (FCM), administered when ... more >>
    V. Abramson, MD
  • Heart Failure — AHA: Myosin Activator Posts ’Modest’ Benefit in GALACTIC-HF – BreakingMED
  • Will another treatment option for heart failure with reduced ejection fraction (HFrEF) soon be added to the armamentarium? A first in class treatment for HFrEF—a myosin activator that improves the contractility or pumping action of the heart—demonstrated a modest 8% reduction in heart failure hospitalizations ... more >>
    V. Abramson, MD
  • EGPA — Flipped CME: Zooming in on Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Real World Practice – Webcast
  • Eosinophilic granulomatosis with polyangiitis (EGPA) is a hypereosinophilic syndrome that affects the small-to-medium sized vessels. EGPA is characterized by asthma, allergies, and a wide range of extrapulmonary manifestations. A rare disease, EGPA can be difficult to recognize and diagnose. Corticosteroids, ... more >>
    P. Seo, MD
    M. Wechsler, MD, MMSc
  • EGPA — Flipped CME: Zooming in on Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Real World Practice – Webcast
  • After years of treatment for severe asthma, the patient in this case develops new and worrisome symptoms. Given a classic presentation of eosinophilic granulomatosis with polyangiitis (EGPA), the patient is readily diagnosed. However, management proves to be challenging. Listen as Dr. Michael Wechsler and Dr. ... more >>
    P. Seo, MD
    M. Wechsler, MD, MMSc
  • EGPA — Flipped CME: Zooming in on Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Real World Practice – Webcast
  • In this case study, a previously healthy, athletic man develops persistent respiratory symptoms and puzzling blood blisters on his lower extremities. A second challenge arises for this patient once treatment is underway, because he is unable to taper from corticosteroids despite experiencing serious adverse ... more >>
    P. Seo, MD
    M. Wechsler, MD, MMSc
  • Cardiology Care Considerations — Right Ventricle Remodeling Predictive of Covid-19 Death – BreakingMED
  • Among patients hospitalized with Covid-19, adverse right ventricular remodeling on transthoracic echocardiography appears to be a significant predictor of mortality, independent of standard clinical and biomarker-based assessment. In a retrospective analysis, RV dysfunction (hazard ratio [HR]: 2.57; 95% CI, 1 ... more >>
    K. Rodowicz, DO
  • Heart Failure — HFSA: EMPEROR Reduced Supports Concomitant Use of SGLT2i and ARNI – BreakingMED
  • For clinicians who may be struggling to decide if they should prescribe an SGLT2 inhibitor or neprilysin inhibitor for their HFrEF patients, Milton Packer, MD, has this advice: "Use both." In this activity based on a HFSA late-breaking clinical trials presentation, Packer makes the case for that advice.
    V. Abramson, MD
  • Heart Failure — HFSA: Drilling Down into VICTORIA Findings – BreakingMED
  • As the list of so-called foundational treatment for reduced ejection fraction heart failure (HFrEF) expands to include four classes of agents (beta-blockers, RAAS inihibitors [ACEi/ARB/ARNI], MRA, and SGLT2 inhibitors), waiting in the wings is a fifth novel agent, which has many clinicians wrestling with a ... more >>
    V. Abramson, MD
  • The Art & Science of Heart Failure Management
  • The Art & Science of Heart Failure Management is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in heart failure ... more >>
    J. Udelson, MD
  • Clinical Context: Stroke Prevention in Atrial Fibrilation
  • Clinical Context: Stroke Prevention in
    Atrial Fibrillation
    is designed to provide up-to-date information on patient identification, risk factors, and current and emerging treatments and best practices in the management of atrial fibrillation.

    The curriculum includes:
    • 6 case studies
    • MedPage Today meeting
    ...
    more >>
    C. Yancy, MD, MSc
  • Cardiology Mastery in Chronic Heart Failure
  • Cardiology Mastery in Chronic Heart Failure is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in chronic heart ... more >>
    C. Yancy, MD, MSc
  • Pulmonary Arterial Hypertension @Point of Care
  • Pulmonary arterial hypertension (PAH) is a rare disorder associated with significant morbidity and mortality. Three PAH treatment pathways or targets have been identified—the endothelin pathway, the nitric oxide pathway, and the prostacyclin pathway. In 1995 the FDA approved the first treatment specifically ... more >>
    R. Channick, MD
  • Heart Failure @Point of Care
  • Heart failure is a significant health burden and, with increasing comorbidities and the aging of the population, this burden is likely to worsen especially in certain populations. Guideline-directed medical therapies have been shown to reduce morbidity and mortality in patients with heart failure, but are ... more >>
    G. Fonarow, MD
  • Hypercholesterolemia @Point of Care
  • The Hypercholesterolemia @Point of Care platform provides comprehensive and current information organized into a progressive series of activities and patient cases covering guideline-recommended diagnostic and treatment strategies with up-to-date clinical trial data and insights from top specialists. ... more >>
    M. Miller, MD
  • Stroke Prevention in Atrial Fibrillation and VTE @Point of Care
  • Stroke Prevention in Atrial Fibrillation and VTE @Point of Care is a clinical decision-making tool that provides a streamlined, comprehensive mobile reference for clinicians to obtain information on the diagnosis, treatment and management of Atrial Fibrillation and VTE. It is made up of a progressive series ... more >>
    S. Connolly, MD, FRCPC
  • Cardiology Care Considerations — Special Considerations in Cardiology for Post Covid-19 Patients – Webcast
  • The World Health Organization declared the novel coronavirus (SARS-CoV 2) outbreak a pandemic on March 11, 2020 and since that time there have been more than 7 million confirmed cases and 200,000 deaths in the United States. Moreover, the disease — Covid-19 — has evolved from primarily a pulmonary disease to ... more >>
    C. Yancy, MD, MSc
  • Heart Failure — ACC: PARAGON-HF Analysis Confirms Predictive Role of NT-proBNP – BreakingMED
  • Is there are case to be made for using ARNI to treat preserved ejection fraction heart failure? Results of the PARAGON-HF trial failed to provide evidence to support that case, yet the findings did point to an undeniable benefit in some groups, and in this report from ACC.2020/WCC Virtual, researchers suggest ... more >>
    V. Abramson, MD
  • Heart Failure — ACC: On Second Analysis, DAPA-HF Benefit Is Durable – BreakingMED
  • Findings from the DAPA-HF trial were a showstopper at the European Society of Cardiology meeting in Paris last year, but that presentation was a time-to-first-event analysis, which may overestimate the treatment benefit. However, this secondary analysis presented at ACC/WCC 2020 shows that this is not the ... more >>
    V. Abramson, MD
  • Heart Failure — ACC: Targeting NO Bioavailability, VICTORIA is Victorious – BreakingMED
  • After years of disappointing results in heart failure trials, clinicians are now being presented with the possibility that another agent—a novel oral soluble guanylate cyclase stimulator—may provide benefit for patients with reduced ejection fraction heart failure, according to the VICTORIA investigators who ... more >>
    V. Abramson, MD
  • Hypercholesterolemia — Ask The Expert: Hypercholesterolemia – Webcast
  • The PCSK9 inhibitors are a class of lipid-lowering agents approved as add-on to statin therapy in very high-risk patients, with the potential to reduce low-density lipoprotein cholesterol by approximately 50% in these at-risk individuals. Despite their proven efficacy, however, these agents are underused in ... more >>
    M. Miller, MD
  • Heart Failure — HFSA: Dapagliflozin Misses Mark for HF Biomarker, But Improves Function – BreakingMED
  • The diabetes drug dapagliflozin may also have a role in reduced ejection fraction heart failure; however, DEFINE-HF results reported at the Heart Failure Society of America meeting in Philadelphia, September 13-16, 2019 delivered mixed findings.
    V. Abramson, MD
  • Heart Failure — HFSA: The Findings Are Positive, But Sacubitril/Valsartan Rx Lags – BreakingMED
  • Trial results, like some other things, can be better appreciated the second time around, which appeared to be the case when investigators for PARAGON-HF and PROVE-HF stepped on stage for encore presentations of their results at the Heart Failure Society of America 2019 meeting in Philadelphia, September 13-16 ... more >>
    V. Abramson, MD
  • Heart Failure — HFSA: Sacubitril/Valsartan Demonstrates Benefit in Hospitalized Black HFrEF Patients – BreakingMED
  • Is treatment with sacubitril/valsartan beneficial for black patients hospitalized with acute decompensated reduced ejection fraction heart failure? A post-hoc analysis of PIONEER-HF found significant improvement in a key biomarker, as well as significant clinical benefit, according to this report from the ... more >>
    V. Abramson, MD
  • Heart Failure — HFSA: Heart Failure Research in the U.S. Is Sub-Optimal – BreakingMED
  • Clinical trials in heart failure treatment are vital for increasing awareness and treatment options; however, U.S. research into HF and other diseases has seen a sharp decline in recent years. This report from the Heart Failure Society of America meeting in Philadelphia, September 13-16, takes a look at the " ... more >>
    V. Abramson, MD
  • Heart Failure — ESC: Unwinding the Mechanism of Clinically Beneficial HF Therapies – BreakingMED
  • Heart failure took and held the spotlight at the ESC 2019 with a series of Hot Line presentations that may have an immediate influence on clinical decisions. This report reviews results of two ARNI studies: PROVE-HF and EVALUATE-HF, as well as an analysis of temporal trends in HFrEF mortality.
    V. Abramson, MD
  • Heart Failure — Patient With Worsening HFrEF and Prediabetes – Case Study
  • Patients with heart failure with reduced ejection fraction (HFrEF) should be managed using guideline-directed medical therapy, and include use of agents that modulate all pathways known to affect HF outcomes. This includes evidence-based beta blockers and agents that inhibit the renin-angiotensin-aldosterone ... more >>
    J. Butler, MD, MPH, MBA
  • Heart Failure — Patient With Worsening HFrEF and Multiple Hospitalizations – Case Study
  • Patients with heart failure (HF) with reduced ejection fraction should be managed using guideline-directed medical therapy, which includes agents that block the renin-angiotensin system, such as angiotensin converting enzymes inhibitors, angiotensin receptor blockers, or angiotensin receptor-neprilysin ... more >>
    J. Udelson, MD
  • Heart Failure — Optimizing Treatment for a Patient With Hypertension and HFrEF – Case Study
  • Patients with heart failure with reduced ejection fraction should be managed using recent clinical trial outcomes and guideline-directed medical therapy (GDMT), which include agents that block the renin-angiotensin-aldosterone system. This case illustrates the real-life clinical scenario of a patient who ... more >>
    K. Ferdinand, MD
  • Heart Failure — Managing a Hispanic Patient With Diabetes, High Cholesterol, and Heart Failure With Reduced Ejection Fraction – Case Study
  • This case demonstrates the real-life clinical scenario of the initial presentation of a patient with heart failure and comorbidities. It demonstrates guideline- and evidence-based diagnosis and treatment of such patients, with emphasis on the need for early initiation of treatment in order to prevent or ... more >>
    Y. Selektor, MD
  • Heart Failure — Managing an Elderly Heart Failure Patient With Hypertension – Case Study
  • This case discusses the real-life clinical scenario of an elderly patient with hypertension and symptoms of heart failure (HF), and describes the common progression of hypertension to HF with advancing age. The case emphasizes evidence-based treatment, as multiple therapies have been shown to be effective for ... more >>
    M. Dunlap, MD
  • Heart Failure — Managing a Heart Failure Patient With Cardiovascular Disease – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with diabetes and hypertension, illustrating the work-up and diagnosis of her cardiovascular disease and heart failure. The case also highlights the guideline-recommended strategies for the treatment and subsequent optimization of medical ... more >>
    E. Hsich, MD
  • Heart Failure — Managing a Patient With Cardiovascular Disease and Severe Renal Impairment – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with symptomatic heart failure and a reduced ejection fraction and renal impairment, and discusses guideline-directed medical therapy for such patients. Patients with renal impairment are eligible for treatment with most of the Class I ... more >>
    E. Hsich, MD
  • Heart Failure — Managing a Hypertensive Black Patient With a Reduced Ejection Fraction – Case Study
  • This case demonstrates the real-life clinical scenario of a black patient with hypertension and heart failure with a reduced ejection fraction, highlighting the guideline-recommended strategies for initial treatment and subsequent optimization in black patients with heart failure.
    J. Udelson, MD
  • Heart Failure — Managing a Patient With a Rapid Heart Beat, Symptomatic HF, and Intolerance to Beta Blockers – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with symptomatic heart failure and a reduced ejection fraction with a rapid heart rate. Guideline-directed medical therapy includes use of beta blockers, but this patient was intolerant to all but a modest dose of these agents. The evidence ... more >>
    J. Udelson, MD
  • Stroke Prevention — Heart Failure Patient with Atrial Fibrillation, Not Previously Treated – Case Study
  • Since patients with atrial fibrillation face a significant increase in the risk of stroke, determining stroke prophylaxis and identifying patients requiring therapy is a high priority. In this case study, Dr. Yancy discusses the risk factors for stroke in patients with heart failure and atrial fibrillation, ... more >>
    C. Yancy, MD, MSc

    We appreciate our customers and hold ourselves to the highest privacy standards.

    Access My Information or Delete My Information